COLLEGE STATION, TX-Texas A&M University and GlaxoSmithKline are teaming up to develop a $91 million, state-of-the-art influenza vaccine manufacturing facility. The facility will anchor Texas A&M's Center for Innovation in Advanced Development and Manufacturing. Groundbreaking details have not yet been released.

In its entirety, the Texas A&M Center for Innovation in Advance Development and Manufacturing is one of three centers established in June, 2012 by the US Department of Health and Human Services to support the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza, and chemical, biological, radiological and nuclear threats.

The CIADM is founded on an initial $285.6 million investment, including a $176.6 million contribution from the US Department of Health and Human Services. The remaining amount is cost-shared by commercial and academic proposal partners. The Center will perform research and advanced development to accelerate vaccines and other medical products through pre-clinical and clinical development and produce these products in cases of pandemics or other national emergencies.

According to a press release, the GSK-A&M partnership is the culmination of investments the State of Texas has made during the past several years in building Texas A&M into a biotechnological powerhouse. Those efforts have led to creation of the Texas Institute for Genomic Medicine at Texas A&M University and the National Center for Therapeutics Manufacturing, also on A&M's campus, which trains bio-pharmaceutical workers.